CN103607983B - Hydrocellular absorbent dressing and the purposes in processing chronic wounds and acute wounds thereof - Google Patents
Hydrocellular absorbent dressing and the purposes in processing chronic wounds and acute wounds thereof Download PDFInfo
- Publication number
- CN103607983B CN103607983B CN201280029311.XA CN201280029311A CN103607983B CN 103607983 B CN103607983 B CN 103607983B CN 201280029311 A CN201280029311 A CN 201280029311A CN 103607983 B CN103607983 B CN 103607983B
- Authority
- CN
- China
- Prior art keywords
- absorbent
- foam
- backing
- dressing
- stiffener
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002250 absorbent Substances 0.000 title claims abstract description 137
- 230000002745 absorbent Effects 0.000 title claims abstract description 131
- 206010052428 Wound Diseases 0.000 title abstract description 39
- 208000027418 Wounds and injury Diseases 0.000 title abstract description 39
- 230000001684 chronic effect Effects 0.000 title abstract description 7
- 230000001154 acute effect Effects 0.000 title abstract description 6
- 238000012545 processing Methods 0.000 title description 4
- 239000006260 foam Substances 0.000 claims abstract description 106
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 59
- 239000003351 stiffener Substances 0.000 claims abstract description 47
- 239000007788 liquid Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000000903 blocking effect Effects 0.000 claims abstract description 8
- 239000004744 fabric Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 25
- -1 polyethylene Polymers 0.000 claims description 17
- 239000000835 fiber Substances 0.000 claims description 15
- 239000011230 binding agent Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000000416 hydrocolloid Substances 0.000 claims description 9
- 229920005830 Polyurethane Foam Polymers 0.000 claims description 8
- 229920001971 elastomer Polymers 0.000 claims description 8
- 239000000806 elastomer Substances 0.000 claims description 8
- 239000011496 polyurethane foam Substances 0.000 claims description 8
- 239000004698 Polyethylene Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 229920000573 polyethylene Polymers 0.000 claims description 7
- 238000003851 corona treatment Methods 0.000 claims description 6
- 238000003475 lamination Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000003292 glue Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 description 49
- 239000010410 layer Substances 0.000 description 46
- 239000000203 mixture Substances 0.000 description 32
- 239000004745 nonwoven fabric Substances 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 239000000853 adhesive Substances 0.000 description 10
- 239000013464 silicone adhesive Substances 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000001070 adhesive effect Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 229920006264 polyurethane film Polymers 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002633 protecting effect Effects 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 229920000247 superabsorbent polymer Polymers 0.000 description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- 241001597008 Nomeidae Species 0.000 description 4
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 238000003490 calendering Methods 0.000 description 3
- 239000004568 cement Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000004447 silicone coating Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920002955 Art silk Polymers 0.000 description 2
- 239000004821 Contact adhesive Substances 0.000 description 2
- 206010051814 Eschar Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229960003872 benzethonium Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 231100000333 eschar Toxicity 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920006267 polyester film Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 230000001012 protector Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FGMPLJWBKKVCDB-BYPYZUCNSA-N (2s)-1-hydroxypyrrolidine-2-carboxylic acid Chemical compound ON1CCC[C@H]1C(O)=O FGMPLJWBKKVCDB-BYPYZUCNSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241001247482 Amsonia Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920002633 Kraton (polymer) Polymers 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 240000007794 Melaleuca viridiflora Species 0.000 description 1
- 235000017710 Melaleuca viridiflora Nutrition 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- SYCBXBCPLUFJID-UHFFFAOYSA-N Pramoxine hydrochloride Chemical compound Cl.C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 SYCBXBCPLUFJID-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000009960 carding Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 229920000359 diblock copolymer Polymers 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- AKFJWRDCWYYTIG-ZDUSSCGKSA-N naproxcinod Chemical compound C1=C([C@H](C)C(=O)OCCCCO[N+]([O-])=O)C=CC2=CC(OC)=CC=C21 AKFJWRDCWYYTIG-ZDUSSCGKSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001691 poly(ether urethane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002742 polystyrene-block-poly(ethylene/propylene) -block-polystyrene Polymers 0.000 description 1
- 229920006306 polyurethane fiber Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 238000002444 silanisation Methods 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229920001935 styrene-ethylene-butadiene-styrene Polymers 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0206—Adhesive bandages or dressings with fluid retention members with absorbent fibrous layers, e.g. woven or non-woven absorbent pads or island dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0213—Adhesive bandages or dressings with fluid retention members the fluid retention member being a layer of hydrocolloid, gel forming material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/022—Adhesive bandages or dressings with fluid retention members having more than one layer with different fluid retention characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/023—Adhesive bandages or dressings wound covering film layers without a fluid retention layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
- A61F13/0279—Apparatus or processes for manufacturing adhesive dressings or bandages by attaching individual patches on moving webs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
- A61F13/0283—Apparatus or processes for manufacturing adhesive dressings or bandages for making adhesive or cohesive tape or fabrics therefor, e.g. coating or mechanical treatments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00217—Wound bandages not adhering to the wound
- A61F2013/00221—Wound bandages not adhering to the wound biodegradable, non-irritating
- A61F2013/00225—Wound bandages not adhering to the wound biodegradable, non-irritating with non-degradable reinforcing layer, net or mesh
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00217—Wound bandages not adhering to the wound
- A61F2013/00229—Wound bandages not adhering to the wound with alginate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00604—Multilayer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00655—Plasters adhesive
- A61F2013/00697—Plasters adhesive elastomer-, e.g. rubber- based
- A61F2013/00702—Plasters adhesive elastomer-, e.g. rubber- based silicon-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00655—Plasters adhesive
- A61F2013/00719—Plasters adhesive adhesives for use on wounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00655—Plasters adhesive
- A61F2013/00723—Plasters adhesive non-adhesive skin fixation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00761—Plasters means for wound humidity control with permeable adhesive layers
- A61F2013/0077—Plasters means for wound humidity control with permeable adhesive layers arranged in lines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00761—Plasters means for wound humidity control with permeable adhesive layers
- A61F2013/00774—Plasters means for wound humidity control with permeable adhesive layers arranged in discrete dots
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00761—Plasters means for wound humidity control with permeable adhesive layers
- A61F2013/00778—Plasters means for wound humidity control with permeable adhesive layers porous layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00761—Plasters means for wound humidity control with permeable adhesive layers
- A61F2013/00782—Plasters means for wound humidity control with permeable adhesive layers with macroscopic openings
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Manufacturing & Machinery (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Materials For Medical Uses (AREA)
- Laminated Bodies (AREA)
- Absorbent Articles And Supports Therefor (AREA)
Abstract
The present invention relates to absorbent dressing, this absorbent dressing comprises ventilative and impervious backing (4) and absorbent foam (2), is particularly well-suited to nurse chronic or acute wounds.The present invention relates to comprise absorbent foam (2) and the dressing of protectiveness backing (4); this protectiveness backing will not pass through liquid but can pass through water vapour; described backing is formed by film (4a) and latticed stiffener (4b) being assembled, and this latticed stiffener is coated with in the way of not blocking the hole in stiffener adhesiveness silicone gel.Additionally, this dressing comprises the non-absorbent web (5) being placed between absorbent foam (2) and backing (4), this non-absorbent web is attached to the adhesiveness silicone gel that is coated on stiffener and is fixed to absorbent foam (2).
Description
Technical field
The present invention relates to comprise applying of ventilative and impervious protectiveness backing and absorbent foam
Expect and (such as, burn in nursing chronic wounds (such as, ulcer or eschar) or acute wounds
Wound) in purposes.
Background technology
For processing the hydrocellular absorbent dressing of wound generally by absorbent foam and can be saturating
The combination of gas and impervious protectiveness backing is constituted.These dressing can contain adhesiveness border, from
And dressing can be fixed to the healthy skin of wound circumference.Direct for avoiding between foam and wound
Contact, these dressing also can comprise the interface layer being positioned on absorbent foam.
Such as,Contact Adhesive absorbent dressing comprises the elasticity of highly-breathable
Polyurethane non-woven fabrics protectiveness backing, the absorbability polyurethane foam being placed in backing central authorities and covering
The discontinuous interface layer of described foam.This interface is by its micro-adhesiveness thus contributes to dressing
Noinvasive use and remove.Contact Adhesive product comprises and bonds with acrylic acid
The sideband (side strip) of agent coating.But, for perilesional skin, it is applied to apply
The acryloid cement on material border has and not satisfied toleration, particularly at chronic wounds
In the case of, perilesional skin is the most fragile.
In the nursing that chronic wounds and acute wounds are carried out, sideband is preferably used and is coated with silicone
The dressing of binding agent, this silicone adhesive agent is more friendly for perilesional skin.But, silicon
Ketone binding agent is completely enclosed, accordingly, it would be desirable to use silicone adhesive agent discontinuously, to guarantee
The fine air permeability of dressing.But, especially in moistening environment, not connecting of silicone adhesive agent
Continuous use that to cause it to adhere to constitute other material of dressing, the particularly ability of absorbent material big
Big reduction.
Therefore, the absorbent dressing of production and application silicone adhesive agent must is fulfilled for the specification of complexity and adjusts
With conflicting feature.The prerequisite main standard of dressing is essentially: good saturating having
While gas, it is to avoid seepage and the risk of dipping, it is impossible to through liquid and antibacterial, have ventilative
Property (that is, can pass through water vapour), retain cohesiveness when removed, and easily manufacture.
Dressing must also be prone to use, and the longest in the case of not damaging perilesional skin
It is retained in temporally in situ, there is high absorbability, and when removed without compromising on wound
Healing.Dressing must also be modelled as the form of patient, and compatible with the support system of supplementary use.
Dressing must also be the most pliable and the toughest, and will not be hardening during absorbing Wound exudate.
If all these character of acquisition simultaneously, the selection that the material constituting dressing is carried out, material phase
Arrangement and the assembling mode of dressing between Hu are extremely complex.
Up to now, the ventilative of cohesiveness and impervious silicone adhesive agent are comprised for obtaining
Dressing, the unique scheme proposed is: only in the one side of tool hole (perforated) polyurethane film
Crosslinking adhesiveness silicone gel, the perforation simultaneously keeping film is open.With acryloid cement or pass through
Heat-sealing, the backing being coated with silicone adhesive agent is fixed on the backing of dressing.
?In Border product, the tool hole being such as coated with adhesiveness silicone gel is gathered
Urethane film is used as interface layer.The discontinuity layer of adhesiveness silicone gel thus covers and is previously placed in the back of the body
Lining form central authorities absorbent foam and be intended to adhere to the backing sideband of skin.Similarly, in application
In WO2010/147533, the discontinuity layer of silicone adhesive agent covers absorbability polyurethane foam and the back of the body
Lining.This discontinuity layer by only in one side the tool hole polyurethane film of silicone-coating gel form.One
Denier crosslinks, and this discontinuous construction makes it possible to avoid that silicone gel is fixed to dressing and absorbs
Layer.It is true that silicone gel once crosslinks, cannot be fixed to commonly use in the way of lasting
In the absorbent foam manufacturing dressing.
But, in this dressing structure, silicone gel directly contacts wound.Silicone adhesive agent covers
Covered the whole surface of dressing the fact that, silicone adhesive agent can not be made to be particularly suitable for covering
The interface layer on absorbent foam surface；Therefore, document US2010/0292626 only proposes
It is coated with silicone adhesive agent and absorbent foam directly contacts the dressing of wound at sideband.For producing
This structure, the polyurethane film being coated with silicone gel cuts into the shape of sideband, uses
Acrylates/ester adhesive is bound to backing film with adhesion.In this dressing, by polyurethane film
Cover with continuous print silicone gel, coat acrylates/ester adhesive discontinuously simultaneously.But,
Owing to cutting and concentrating the step of each composition, the production of this dressing is the most complicated.
Accordingly, it would be desirable to manufacture is not through liquid but has high osmosis to water vapour and use silicon
The dressing of ketone binding agent, described dressing is easier to preparation compared with this kind of dressing of the prior art, and
And cohesiveness is retained from wound when removing.
Summary of the invention
Applicants have found that be fixed to absorbent foam to be coated with on the backing of silicone gel new
Method, this method makes when dressing is dried and when dressing has loaded Wound exudate, group
Each material of dress has the cohesive strength of enough levels.This dressing also ratio uses silicone to glue in prior art
The dressing of mixture is easier to preparation.By means of this dressing, need not cover with adhesiveness silicone gel
The whole surface of dressing, thus simplify the technique manufacturing dressing, thus can be optionally by wound more
Other friendly interface layer is applied to foam.
Therefore, subject of the present invention is to comprise absorbent foam and the dressing of protectiveness backing, this guarantor
Protecting property backing is not through liquid but can pass through water vapour:
-described backing is by by continuous film and latticed stiffener (openwork reinforcement)
Assemble and formed, not block hole in described stiffener at least one face of described stiffener
Mode is coated with adhesiveness silicone gel, the whole surface of described stiffener coverlay；
-described dressing also comprises the nonabsorbable being inserted between described absorbent foam and described backing
Net, this non-absorbent web adheres to the adhesiveness silicone gel being coated on described stiffener, and solid
Fixed extremely described absorbent foam, the most only periphery along described absorbent foam is fixed.
Owing to (being coated with the most discontinuously with silicone gel coating on the whole surface of one face
Cover) backing do not adhere to absorbent foam, so non-absorbent web be the present invention necessarily
Element.In the case of using acrylates/ester adhesive, can not be assembled to be coated with silicone by foam
The backing of gel.
Such as, with schematic angle, this type of dressing is described in accompanying drawing 1 to accompanying drawing 3.
In these figures, dressing is illustrated in cross-section.
Accompanying drawing explanation
In FIG, absorbent foam 2 is protected by stripping type being coated with on the side of wound
The discontinuous interface layer 1 of thing (peel-off protector) 3 protection.
Backing 4 be can pass through the film 4a of water vapour and latticed stiffener 4b group by being not through liquid
Dress is formed, and described latticed stiffener is coated with viscous in the way of not blocking the hole in described stiffener
Attached property silicone gel.By inserting non-absorbent web 5, backing 4 is fixed to absorbent foam 2.
In figs. 2 and 3, absorbent non-woven cloth 6 is inserted into net 5 and absorbent foam 2 it
Between.In the way of wrapping absorbent non-woven cloth 6, it is fixed to net 5 along its periphery absorb sex vesicle
Foam 2, the size being smaller in size than absorbent foam of absorbent non-woven cloth 6.
In fig. 2, backing has the size identical with absorbent foam；And in Fig. 1 and Fig. 3,
Backing is wider compared with absorbent foam and non-absorbent web, to form the adhesiveness that can adhere to skin
Edge or border.
Detailed description of the invention
Water vapour preferably through liquid and outside pathogenic microorganism, but will not be had by backing simultaneously
Permeability, to avoid wound and outside liquid and antibacterial contacts and the dipping of wound.By this
Backing is referred to as " ventilative and impervious backing ".
Preferably backing is thin and flexible, it is thus possible to be preferably modelled as body shape, and can move
Without there being the risk of disengaging.Backing preferably closes shape (conformable).The thickness of backing can be
100-600 μm, preferred 250-500 μm.
As dressing of the present invention a part backing by continuous film 4a and latticed stiffener 4b
Composition, described latticed stiffener is coated with adhesion in the way of not blocking the hole in described stiffener
Property silicone gel.For in the sense that it is without perforation step, this film is continuous print.
Film can be replaced with foam/membrane complex or fabric/membrane complex.In available film, pass through
The mode enumerated can be mentioned that poly(ether-urethane) film, polyetheramides film or polyether ester film.
The thickness of film for example, 5-200 micron, preferred 10-75 micron, more preferably 10-50 micron.
Continuous film is not through liquid, but can pass through water vapour.Continuous film can be that breathable is not permeable
Permeable membrane or aforesaid compounds, such as, be usually used in manufacturing the continuous film of absorbent dressing.Film preferably has
More than 3000g/m2/ 24 hours, preferably greater than or equal to 7000g/m2/ 24 hours, more preferably greater than
Or equal to 10000g/m2The moisture vapor transmission rate (MVTR) of/24 hours.Latticed stiffener is not to block up
The mode filling in the hole in described stiffener is coated with silicone compounds.Select the most as follows by
This stiffener of this coating: keep gratifying, particularly greater than or equal to 4000g/m2/24
Hour, preferably greater than or equal to 5000g/m2The backing moisture vapor transmission rate value of/24 hours.?
NF-EN13726-2 standard (the 3.3rd chapter) describes the measurement moisture vapor transmission rate when liquid contacts
Technology.
When dressing comprises sideband, will not be rolled by backing self after removing stripping type protection
Mode, stiffener can make backing hardening, described stripping type protection be optionally used for protect foam
Or interface layer and/or adhesiveness border.
Stiffener can be made up of any lattice-like material, such as membrana fenestrata, thermoplastic web, fabric (example
Such as yarn fabric, fabric or non-woven fabrics), for making dressing preferably be maintained on skin, preferably elastic
Material.Such as, membrana fenestrata is made up of polyethylene or polypropylene.Such as, yarn fabric is by gathering benzene two
Formic acid glycol ester or polyamide are made.Every Gram Mass (grammage) of stiffener is preferred
For 10-500g/m2, such as 20-300g/m2.Can be on the one side of stiffener, two sides or the most whole
Surface-coated silicone gel.The size in stiffener hole can be 0.1-5mm, such as 0.5-3mm.Add
Gu the hole surface of thing preferably comprises the 1-99% on continuous film surface, preferred 25-90%, more preferably 30-80%；
Once the hole surface of stiffener is coated with silicone gel, and described hole surface preferably comprises continuous film surface
10-99%, preferred 10-60%, more preferably 25-75%.
According to an embodiment, use fabric, preferably with not on the whole surface of fabric
The mode blocking the hole in described fabric is coated with silicone gel.Such as by fabric is dipped in
In silicone gel precursor mixture, make whole fabric group (mass) silicone-coating gel.
According to another embodiment, described stiffener is membrana fenestrata, and described membrana fenestrata is only in its one side
On in the way of not blocking the hole in described membrana fenestrata silicone-coating gel, such as can by heating,
Ultrasonic, high-frequency therapeutic treatment or binding agent are fixed to the tool hole polyurethane film of continuous film.
Adhesiveness silicone gel is the silicone compounds that structure crosslinks.Silicone gel demonstrates viscous
Poly-power, thus when removing dressing, residue will not be left on skin, and remain to be attached to add
Gu thing.Can crosslink after being contacted with each other by silicone precursor, the most hydrogenated silanization or condensation are anti-
Silicone gel should be manufactured.In the prior art, such as document EP-A-0 251 810, EP-A-0 300
This type of system known in 620 or US-A-4 921 704.In the precursor mixing described in described document
Thing substantially comprises:
-component A and platinum catalyst, described component A is included in it and respectively holds by vinyl substituted extremely
Few a kind of polydimethylsiloxane, and
-component B, described component B is for comprising at least two hydrosilanes (hydrosilane) group
Polydimethylsiloxane.
Two kinds of components are put together, causes the two functionalized poly dimethyl siloxane to hand over
Connection reaction, described cross-linking reaction is carried out the most at ambient temperature and can be accelerated by heating.
Can at least one in the two component blast blending, such as pigment, inhibitor
Or loose filler (bulking fillers).
The precursor of adhesiveness silicone gel is selected from following products: from Bluestar Silicones's
Silbione RT4712A&B and Silbione RT4717A&B；From
The Wacker of Wacker-Chemie GmbH612；From Nusil Technology'sMED-6340、MED-6345、MED3-6300 or
MED12-6300；And from Dow Corning's
According to the method for EN1939, preferably so that skin is had more than 40cN/cm, excellent by backing
Select the mode of the adhesion of 45cN/cm, select silicone gel.By a width of 20mm, a length of 150mm
Backed samples be placed on forearm.After 10 minutes, with the angles of 90 ° in the stretching of 900mm/min
Under speed, measure adhesion with ergometer.
Preferably silicone gel is applied in the way of not blocking the hole in stiffener latticed reinforcing
Thing, every Gram Mass of described silicone gel is 100-500g/m2, preferred 150-250g/m2,
To take into account enough moisture vapor transmission rates and to continuous film or enough cohesive strengths of skin.
By the way of enumerating, the backing being made up of following combination can be used: have about
7000g/m2The polyurethane film of 30 μ m-thick of/24 hours moisture vapor transmission rates and with 200g/m2Ratio
Example silicone gel is at the 40g/m of its whole surface-coated2The combination of braided polyester thing.This backing
Thickness be about 400 μm, MVTR is about 5000g/m2/ 24 hours.
In one embodiment, the size of backing is more than the size of absorbent foam and described
Foam occupy the central authorities of backing, thus produces adhesiveness border.
Dressing of the present invention comprises the net being inserted between absorbent foam and backing, and being used for will
Described absorbent foam and backing assemble.The most in a humid environment, owing to being coated with
The backing surface of adhesiveness silicone gel can not fully adhere to absorbent foam, and therefore this is fixed
Means are required.
The net being inserted between absorbent foam and backing is the non-suction with low every Gram Mass
The property received non-woven fabrics.This non-woven fabrics can be any type non-woven fabrics being usually used in health and dressing field,
Particularly filature fleece formation non-woven fabrics, carding non-woven fabrics or spun-laced nonwoven fabric (spun laid, carded
Or spun lace nonwoven).Every Gram Mass of described net is preferably 15-50g/m2, preferably
20-40g/m2。
Do not contain such as artificial silk, viscose glue or the absorbency fiber of cellulose derivative at net and do not contain
For having in the sense that absorbent particles, this net is non-absorbent web.
Net can comprise Fypro, polyester fiber, polyurethane fiber and/or polyolefine fiber.Root
According to an embodiment, net comprises polyethylene fibre.Described fiber can be homofil or
Core/shell type or parallel type two component fibre.Such as may select filature fleece formation non-woven fabrics, preferred spunbonded type
(spun bond) filature fleece formation non-woven fabrics.
Non-absorbent web is preferably made up of hydrophobic fibre, but also can be made up of and warp hydrophilic fibre
Crossing process makes non-absorbent web become hydrophobicity.As long as its porosity is enough, net can be constituted by several layers,
The layer contacted with adhesiveness silicone gel is non-absorbent, the most hydrophobic.
By conventional technique for fixing (as heating, ultrasonic, high-frequency therapeutic treatment or with binding agent), by non-
Absorbent web is fixed on the whole surface of absorbent foam or the most only along the limit of absorbent foam
Edge is fixed.
In the context of the present invention, the every Gram Mass being made up of polyethylene fibre is such as used
For 30-40g/m2Spun-bonded non-woven fabrics, as Freudenberg company withLSO1040
The product of WEISS sold.
In the context of the present invention, absorbent foam be selected from by mix absorbent particles and have
Absorbent Hydrophobic adsorption sex vesicle foam and hydrophilic absorbent sex vesicle foam.
Patent application WO96/16099, WO94/29361, WO93/04101, EP420 515,
EP392 788, EP299 122 and WO2004/074343 describe those skilled in the art public
The hydrophilic absorbent sex vesicle foam known and manufacture method thereof.Such as, this class A foam A corresponds to AMS company
The 562-B of MCF03 or the RYNEL Company sold.
An optimal way according to the present invention, uses hydrophilic polyurethane foam, according to desired
Absorbability select foam thickness.In the context of the present invention, particularly most preferred thickness
Polyurethane foam for 1.5-5mm.
If being designed to increase the absorbability of dressing, can by aforesaid foam with selected from foam,
Second absorbent layer of absorption fabric (such as yarn fabric or fabric or non-woven fabrics fabric) is tied mutually
Close.
A mode according to the present invention, uses foam 2(such as hydrophilic polyurethane foam) and inhale
The combination of the property received non-woven fabrics 6.As shown in Figures 2 and 3, preferably by described absorbent non-woven cloth
It is placed between absorbent foam and net.Little according to this modification, the preferably size of absorbent non-woven cloth
In the size of foam, thus the edge that absorbent non-woven cloth wraps up into being made up of net and foam is fixed
Jacket in.
Absorbent non-woven cloth is preferably by absorbency fiber (such as cellulose, artificial silk or viscose rayon)
Composition.Preferably obtain non-woven fabrics by dry process (referred to as " air lay ").
Conventional all adhesive pattern in this technique are used equally to the non-woven fabrics of the present invention: pass through
Spraying latex adhesive；By mix heat-bondable fibre or powder, the most heated process and bond；Logical
Cross and combine both technology and bond；Bonded by the simple compression of fiber.Preferably need not mix
Enter last a kind of adhesive pattern of thermo-adhesive materials or latex.
According to an embodiment of the invention, absorbent non-woven cloth is to account for non-woven fabrics gross weight
1wt%-70wt%, preferred 25wt%-55wt% ratio mixed with superabsorbent polymer particles.Super
Strong absorbent polymer is selected from acrylate copolymer, including the salt of acrylate copolymer (such as poly-third
Olefin(e) acid sodium).
According to a preferred embodiment of the present invention, use based on superabsorbent polymer particles
It is not incorporated into the non-woven fabrics of thermo-adhesive materials or latex, at described non-woven fabrics with cellulose fibre
Cover with net based on cellulose on each.According to another modification of the present invention, also can be by such as
Lower non-woven fabrics is used as absorbent non-woven cloth: be made up of two nets based on cellulose, and described
Superabsorbent polymer particles is individually mixed or by superabsorbent polymer particles between two nets
Mix with binding agent combination.
Absorbent non-woven cloth also can comprise superabsorbent fiber.
In the context of the present invention, following non-woven fabrics is preferably used: there is the thickness of 0.5-3mm；
And/or there is 200-500g/m2Every Gram Mass；And/or have more than 5000g/m2, more excellent
Choosing is more than or equal to 7000g/m2Absorbability.Described absorbability can be according to EDANA
440.1.99 standard measures.
Suitably absorbent non-woven cloth for example, EAM Corporation Company is entitledAbsorbent non-woven cloth.
Preferably the discontinuous interface layer 1 being intended to Wound contact is placed in the table of absorbent foam
Face is also in the face of wound.This interface layer is discontinuous, to allow exudate to enter absorbent foam.When
When removing dressing, this interface layer will not change wound devastatingly.
According to an embodiment of the invention, dressing does not comprise sideband, and interface layer is micro-viscous
It is attached to wound.I.e. it is capable of dressing to be fixed to wound temporarily, and described apply be can be removed
Expect the structure without changing perilesional skin or wound devastatingly, so that this dressing can
Reorientate and be conducive to nursing.This fixing can assist nursing staff or user supporting method,
Adhesive plaster, ribbon (strip) or fixing net (holding net) cover dressing.
The composition of interface layer can be the composition of hydrophobicity, hydrophilic or both sexes.
Thus can be mentioned that: compositions based on silicone polymer (particularly silicone gel), poly-ammonia
Gels, containing hydrocolloid (or even hydrogel, such as based on poly-(AMPS) hydrogel)
Based on elastomer compositions.
In the context of the present invention, particularly preferably use containing elastomer, plasticizer and hydrocolloid
The discontinuity layer of compositions.This interface layer is by being maintained in the wet environment of wound level
Promote agglutination, and can delivery of active agents, the interface layer of silicone coated cannot accomplish this
A bit.
Elastomer is selected from poly-(styrene-olefin-styrene) being optionally combined with diblock copolymer
Triblock polymer.Triblock copolymer can be that poly-(styrene ethylene-propylene-styrene) (is called for short
SEPS) block copolymer or withG1651、G1654 orPoly-(styrene-ethylene-butylene-styrene) (being called for short SEBS) of G1652 sold
Block copolymer.
In the plasticizer compounds that can use, can specifically mentioned mineral oil, polybutene or neighbour
Phthalate/ester derivant.Particularly preferably use selected from933 HesMineral plasticising oil in the product of 919 sold.
As suitable hydrocolloid, such as, can be mentioned that pectin, alginate/ester, natural plant (example
In particular such as POLY-karaya), cellulose derivative (such as carboxymethyl cellulose and alkali metal salt thereof,
If the sodium salt of carboxymethyl cellulose is (with CMC7H4XF title is known) or calcium
Salt) and synthetic polymer based on superabsorbent acrylates (such as BASF AG withThe product of 1003 sold, CIBA Specialty Chemicals company withSC91 product sold) and the mixture of these compounds.
The release of the activating agent for being optionally present in optimum organization thing, wettability or gelling speed
Degree, if required, the compound based on elastomer containing hydrocolloid can comprise one or more
Antioxidant and the surfactant of SEPPIC Company80 or polymerization
ThingEMT10。
If it is desire to interface layer has micro-adhesiveness or adhesiveness, containing hydrocolloid based on elasticity
The compositions of body includes thickening product, and this thickening product is selected from tackifying resin, low-molecular-weight
Polyisobutylene or their mixture.Generally preferably use hydrogenated resin, such as 5000 seriesResin, particularly5380 resins.
Compositions can include the active component beneficially processing wound.Can be used for the context of the invention
Material in, can be mentioned that in the way of enumerating:
-antibacterial agent, such as silver derivant, such as silver or salt (the such as silver sulfate, chlorine of other metal
Change silver or silver nitrate and silver sulfadiazine), silver or complex (the such as silver boiling of other metal
Stone (such as alphasan) or pottery)；Metronidazole (metrodinazole)；Neomycin；Many Acarasiales
Element B；Penicillin (amoxicillin)；Clavulanic acid；Tetracycline；Minocycline；Chlortetracycline；Ammonia
Base glucosides class；Amikacin；Gentamycin；Or probiotic bacteria；
-anti-corrosion additive, such as chlorhexidine, triclosan, biguanide, Hexamidine, thymol, lugol, gathers
Dimension ketone iodine (iodinated povidone), benzalkonium chloride and Benzethonium (benzethonium)；
-analgesic, as acetaminophen, codeine, dextropropoxyphene, tramadol, morphine and
Its derivant, corticosteroid and derivant；
-antiinflammatory, such as glucocorticoid, non-steroidal antiinflammatory agent, aspirin, ibuprofen, ketone Lip river
Sweet smell, flurbiprofen, diclofenac, aceclofenac, ketorolac, meloxicam, piroxicam,
Tenoxicam, naproxen, indomethacin, HCT 3012, nimesulide, celecoxib, support
Former times cloth, Parecoxib, rofecoxib, Valdecoxib, Phenylbutazone, niflumic acid and mefenamic acid；
The activating agent of-promotion healing, such as retinol, VitAVitE, N-acetyl group hydroxyl
Proline, Herba Centellae (Centella Asiatica) extract, papain, thyme oil,
Rhizoma Melaleuca Viridiflora quintessence oil, rosemary ethereal oil and Herba Salviae Japonicae essential oil, hyaluronic acid, poly-sulfated oligosaccharide
And salt (particularly has the synthesis sulfated oligosaccharide of 1-4 monosaccharide unit, such as sucrose eight sulfur
Acid potassium salt or sucrose octasulfate silver salt), sucralfate, allantoin, carbamide, metformin, enzyme (example
Such as proteolytic enzyme, such as streptokinase, trypsin or collagenase), peptide or protease inhibitor；
-anesthetis, such as benzocaine, lignocaine, dibucaine, Pramoxine HCL, cloth ratio
Caine, mepivacaine, prilocaine or etidocaine.
Based on elastomer micro-adhesive composition containing hydrocolloid, described compositions are preferably used
Comprise (adding up to 100wt%):
0.05wt%-1wt% antioxidant；
10wt%-60wt% tackifying resin；
2wt%-20wt%, preferred 12-16wt% sodium carboxymethyl cellulose；
10wt%-65wt% plasticising mineral oil；
5wt%-25wt% poly-(styrene-ethylene-butylene-styrene) or poly-(styrene ethylene-propylene-
Styrene) triblock polymer；And
1wt%-15wt% is by 2-methyl-2-[(1-oxo-2-acrylic) amino]-1-propane sulfonic acid salt and propylene
The copolymer of acid 2-hydroxy methacrylate composition.
Another hydrocolloid elastic composition can comprise (adding up to 100wt%):
0.05wt%-1wt% antioxidant；
2wt%-20wt%, preferred 12wt%-16wt% sodium carboxymethyl cellulose；
20wt%-65wt% plasticising mineral oil；And
3wt%-25wt% poly-(styrene-ethylene-butylene-styrene) or poly-(styrene ethylene-propylene-
Styrene) triblock polymer.
At least at absorbent foam or be coated with the absorbent foam of interface layer and be intended to contact wound
On surface, with protecting film-paste layer to described absorbent foam or the absorption sex vesicle that is coated with interface layer
Foam is protected by, and described protecting film-paste layer can remove by peeling off before using dressing.
Stripping type protection 3 can be made up of one or more ingredients, can shell before the use
From.In the case of dressing comprises the sideband of binding agent coating, this protection covers absorbent foam
Whole surface or all surface of backing.
This protection can be any material that dressing skilled person is commonly used for protection.Such as,
This protection can be at the form of film and (is such as made up of polyolefin (such as polyethylene or polypropylene)
Film or polyester film), may also be in the form of paper.Preferably at least one face of this film, use silicone
Compound (such as silane), fluorine compounds or fluorosilicone compound process.
This protection should be suitable for micro-sticking property of interface layer.If backing comprises sideband, suitable
In the case of when, this protection also should be suitable for the character of the adhesiveness silicone gel of described backing.
In the context of the present invention, the most double ingredient formulas are particularly preferably used
Protection (two-part protector).
The thickness of stripping type protection is preferably 10-100 μm, e.g., from about 50 μm.
Preferably by Siliconature company withThe product of M1R88001 sold is used as
This type of stripping type protection.
The dressing of the present invention be advantageously applied to process all of exudative chronic wounds (eschar,
Ulcer (such as diabetic foot ulcer)) and acute wounds (second degree burns, scratch (dermabrasion),
Traumatic wounds, postoperative wound).
When comprising adhesiveness sideband, the dressing of the present invention is particularly well-suited to when perilesional skin
Time fragile, wound is processed.
In the context of the present invention, for avoiding departing from too early, the dressing with fillet is preferably used.
The dressing of the present invention can be at small size or the form of large-sized independent dressing.Dressing is only
In the vertical packing material being packaged in sealing, it is ensured that dressing preserves in gnotobasis.
Subject of the present invention is also the method preparing aforementioned dressing, and the method is produce backing and incite somebody to action
Backing is assembled to absorbent foam.According to an embodiment, absorbent foam is fixed to non-suction
The property received net, then by making the contact of described non-absorbent web be coated with the support of adhesiveness silicone gel
Thing side, thus assembly is assembled to backing.Such as, in calendering (calendered) to backing
Before, absorbent foam and non-absorbent web are carried out heat seal.
In the first step, by coating stiffener and the stiffener after coating is assembled to continuous film and
Produce backing.
One in the paint-on technique that use those skilled in the art commonly use, coats silicone gel extremely
On stiffener.
According to the optimal way of the present invention, by silicone gel coating to two faces of stiffener.I.e.
Make gel the most fully crosslinked, it is possible to be assembled on continuous film by described stiffener, to guarantee described film
And the cohesive strength between latticed stiffener.In this embodiment, it is not necessary to binding agent can be by
Stiffener adheres to be not through liquid but can pass through the film of water vapour.
In this approach, step in the following order backing can be manufactured:
-use the mixture of silicone gel precursor to cover two faces of stiffener；
-stiffener is assembled to film, such as carried out by calendering；And
-once stiffener and film assembling, makes silicone gel crosslink or accelerates its crosslinking, the most logical
Cross to be positioned in baking oven backing and carry out.
Such as, stiffener is immersed in the mixture of silicone gel precursor, then at Lamination station
Extrude between two rollers in (lamination station).The hole of air feeder restructural stiffener,
Thus remove the silicone gel of surplus.
In another way, silicone gel is coated on a face to two faces of stiffener, and
By binding agent, another side is fixed to continuous film.Enter also by heating, ultrasonic or high-frequency therapeutic treatment
Row is fixing, and in this case, stiffener and/or continuous film can be thermoplastic, in order to will
They heat seals.
Described backing can be protected by covering the adhesiveness face of backing with protective layer or film-paste layer.Example
As, this protective layer can be paper or polyester film.
In second step, non-absorbent web is fixed to absorbent foam.Before superposition, will bubble
The volume of foam volume and non-absorbent web launches and relaxes.By heating, ultrasonic, high-frequency therapeutic treatment or with viscous
Net and foam are fixed together by mixture only edge along them.For example, it is preferable to by heating or high
The whole edge that frequency processes along foam block carries out heat seal.Seal temperature e.g. 80 DEG C-150 DEG C,
More preferably 90 DEG C-120 DEG C, the most about 110 DEG C.Net and foam fixing the most only along foam
Edge (such as, with the width of 1-3mm) is carried out.Then carry out delaminate (stripping) so that
Foam preferably can be optionally cut with square shape, without switching to net along depth of foam.
Subsequently, by applying 0-10bar, the setting pressure of preferred 0-6bar, in Lamination station
The foam being fixed to net is assembled into previously fabricated backing.Described Lamination station preferably strikes out
Shape workshop section (drawing station).
Before cutting, it is intended at absorbent foam contact on the side of wound, by protecting film-patch
Layer covers backing/net/foam assembly, and described protecting film-paste layer can be by stripping before using dressing
From and remove.
If absorbed layer covers by interface layer and temporary transient stripping type protection in advance, described temporarily
Protection will be removed, thus interface layer be intended to contact wound side on, with protection
Film-paste layer covers backing/net/foamed materials/boundary layer assembly, and described protecting film-paste layer can use
Remove by peeling off before dressing.
When non-absorbent web is fixed to foam by expectation binding agent, rolling with froth bed
Before process, launch and lax non-absorbent web with binding agent coating.Then delaminate,
And under conditions of as hereinbefore, assembly is fixed to backing.
According to an embodiment, when dressing contains absorbent non-woven cloth, will be derived from foam volume,
The volume of non-absorbent web and the volume of absorbent non-woven cloth, through launching and lax material superposition.This
Three layers all will be through two continuous print delamination step, to be switched to than foam more by absorbent non-woven cloth
Little size.If non-woven fabrics contains superabsorbent polymer particles, preferably by net and absorbability
Foam carries out heat seal.
Once net and absorbent foam are interfixed, preferably by laminating method as hereinbefore
Assembly is assembled to backing.The selection of non-absorbent web of the present invention is preferably able to without such as existing
Have and technology equally depends on acryloid cement and backing and net are assembled.When dressing contains
Adhesiveness sideband, dressing after a procedure was removed or when skin departs from, backing and nonabsorbable
Net still remains attached to together.
Preferably net is being fixed in the step before backing, net and absorbent foam is being interfixed,
To avoid weakening silicone gel.
According to an embodiment, preferably before non-absorbent web is faced being fixed to absorbent foam,
Described non-absorbent web preferably carries out sided corona treatment (corona treatment).Sided corona treatment makes it possible to
Enough strengthen the attachment of the net backing to being coated with adhesiveness silicone gel.In this embodiment,
Net can be made up of polyethylene fibre.
Preferably before absorbent foam is fixed to non-absorbent web, cover described with interface layer
Absorbent foam.
Such as, as it was noted above, interface layer can be containing based on elastomer compositions and containing water
Colloid.Can be according to well known to a person skilled in the art heat fusing method, by each constituent is existed
Carry out hot mixing at a temperature of 90 DEG C-160 DEG C, preferably 110 DEG C-140 DEG C, manufacture said composition.
Preferably the cylinder (etched cylinder) being etched is dipped in the compositions carrying out hot mixing in advance,
Then will keep the compositions demoulding of high temperature and be transferred on absorbent foam.The group of high temperature will be kept
Compound applies can optimize the attachment of interface layer to absorbent foam.Then step of delaminating is being carried out
Before Zhou, temporary transient protection is placed on the foam being coated with interface layer.By foam/net group
After piece installing is fixed to backing, temporary transient protection is removed, thus uses stripping type protection,
Described stripping type protection removed before by dressing application to skin.
Embodiment
By following example, the present invention will be described.
Embodiment 1: the preparation of absorbent dressing
Manufacture and comprise the dressing of following material: micro-adhesiveness interface layer, absorbent foam and gas
Stream becomes net non-woven fabrics, nonabsorbable polythene net, the backing being coated with adhesiveness silicone gel and stripping
From formula protection.
Use following material:
-backing, described backing is 40g/m2Braided polyester thing, at two of this braided polyester thing
On face and it is coated with adhesiveness silicone gel (200g/m on whole surface2), described backing is laminated
On the polyurethane film of 30 μ m-thick.This backing has thickness and the about 5000g/m of about 300 μm2/24
Hour MVTR.
-non-absorbent web, described non-absorbent web for example, Freudenberg withLSO
The 40g/m of 1040WEISS sold2Polyethylene nonwoven.
-absorbent foam, described absorbent foam is that CORPURA is with MCF03 sold
3mm hydrophilic polyurethane foam.
-absorbent non-woven cloth, is inserted into described absorbent non-woven cloth between net and foam, described suction
The property received non-woven fabrics is the air-laid nonwoven fabrics (200g/m containing super absorbent polymer2), institute
State air-laid nonwoven fabrics by EAM Corporation withSold.
-fluorosilicone-paste layer PET stripping type protection, described protection thickness is 50 microns, by two
Individual aerofoil form, described protection by SILICONATURE withM1R88001 name
Claim supply.
The preparation of interface layer and the coating on absorbent foam thereof:
Prepare following compositions (by based on the wt% of gross weight):
-mineral oil, by Shell company with919 sold: 39.7%
-sodium carboxymethyl cellulose, by AQUALON company with CMC7H4XF name
Claim to sell: 14.8%
-poly-(styrene-ethylene-butadiene) block copolymer, by KRATON company with
G1651E sold: 4.7%
-antioxidant, by CIBA SPECIALTY CHEMICALS company with
1010 sold: 0.2%
-2-methyl-2-[(1-oxo-2-acrylic) amino]-1-propane sulfonic acid salt and acrylic acid 2-hydroxy methacrylate
The copolymer of (releasing agent), by SEPPIC company withEMT10 sold:
5%
-tackifying resin, by EXXON CHEMICALS company with5380 titles
Sell: 35.6%.
In MEL G-40 blender, add mineral oil, hydrocolloid and elastomer, be subsequently adding anti-
Oxidant and releasing agent (releasing agent), be eventually adding tackifying resin, be heated to 100 DEG C
The temperature of-110 DEG C, thus obtain uniform mixture.
By aforementioned mixture with 170(± 40) g/m2Amount coat discontinuously to hydrophilic polyurethane
On foam.
The assembling of layer:
-make the sheet material of polyurethane net carry out sided corona treatment under conditions of following:
-generator power: 570 watts；
-electrode number/width: 3/0.25m；
-gap adjusts: 2mm；
-the speed of service: 2m/ minute.
-sided corona treatment effect disappear before, with AMIS hand seamer only in side with 2mm
Width net and hydrophilic polyurethane foam are sealed, then absorbent non-woven cloth is inserted into
Between foam and net.
-under conditions of as hereinbefore, its excess-three side is carried out seal operation, to form 8 × 8cm
Square, be then sliced out the edge of assembled complex.
-backing is cut to the square of 15 × 15cm, then on both vertical directions, pass through
Roll with the roller of 10kg, backing is assembled to aforesaid complex.
-cut out the final dressing with fillet of 13 × 13cm.
Claims (14)
1. a wound dressing, described dressing comprise absorbent foam (2) and be not through liquid but
Can pass through the protectiveness backing (4) of water vapour；
-described backing (4) is by assembling shape by continuous film (4a) and latticed stiffener (4b)
Become, at least one face of described stiffener is coated with in the way of not blocking the hole in described stiffener
Being covered with adhesiveness silicone gel, described stiffener covers the whole surface of described continuous film；
-described wound dressing also comprises and is inserted between described absorbent foam (2) and described backing
Non-absorbent web (5), described non-absorbent web adheres to be coated on described stiffener (4b)
Described adhesiveness silicone gel, and it is fixed to described absorbent foam (2).
2. wound dressing as claimed in claim 1, it is characterised in that described non-absorbent web (5)
Every Gram Mass be 15-50g/m2。
3. wound dressing as claimed in claim 1, it is characterised in that described non-absorbent web (5)
Comprise polyethylene fibre.
4. wound dressing as claimed in claim 1, it is characterised in that described absorbent foam (2)
Occuping the central authorities of described backing (4), the surface of described backing (4) is more than described absorbent foam
(2) surface, thus produce adhesiveness border.
5. wound dressing as claimed in claim 1, it is characterised in that described absorbent foam (2)
For hydrophilic polyurethane foam.
6. wound dressing as claimed in claim 1, it is characterised in that described adhesiveness silicone coagulates
Every Gram Mass of glue is 100-500g/m2。
7. wound dressing as claimed in claim 1, it is characterised in that at described absorbent foam
(2) on the surface of wound, described absorption sex vesicle is covered with discontinuous interface layer (1)
Foam (2), described interface layer (1) comprises elastomer, plasticizer and hydrocolloid.
8. the wound dressing as according to any one of claim 1-7, it is characterised in that described net
Trellis stiffener (4b) is fabric, on two faces of described fabric and at described fabric
Whole surface on be coated with in the way of not blocking the hole in described fabric adhesiveness silicone coagulate
Glue.
9. the wound dressing as according to any one of claim 1-7, it is characterised in that described net
Trellis stiffener (4b) is membrana fenestrata, not block described tool on a face of described membrana fenestrata
The mode in the hole in pore membrane is coated with adhesiveness silicone gel.
10. the method for the wound dressing according to any one of manufacturing claims 1-9, described method exists
In: produce described backing (4), by described non-absorbent web (5) and described absorbent foam (2)
Fixing to form assembly, then assembly is assembled to described backing (4).
11. methods as claimed in claim 10, it is characterised in that by heating, ultrasonic or use
Binding agent only along the edge of described non-absorbent web (5) and described absorbent foam (2) by described
Non-absorbent web (5) is fixed together with described absorbent foam (2).
12. methods as claimed in claim 10, it is characterised in that by high-frequency therapeutic treatment only along institute
State the edge of non-absorbent web (5) and described absorbent foam (2) by described non-absorbent web (5)
It is fixed together with described absorbent foam (2).
13. methods as according to any one of claim 10-12, it is characterised in that in lamination work
Duan Zhong, by applying the pressure of 0-10bar, is assembled to described backing (4) by described non-absorbing
The described assembly that property net (5) and described absorbent foam (2) form.
14. methods as according to any one of claim 10-12, it is characterised in that fixing facing
Before described absorbent foam, described non-absorbent web (5) is carried out sided corona treatment.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1153325 | 2011-04-15 | ||
| FR1153325A FR2974004B1 (en) | 2011-04-15 | 2011-04-15 | HYDROCELLULAR ABSORBENT DRESSING, ITS USES FOR THE TREATMENT OF CHRONIC AND ACUTE WOUNDS |
| PCT/FR2012/050811 WO2012140377A1 (en) | 2011-04-15 | 2012-04-13 | Hydrocellular absorbent dressing, and uses thereof for the treatment of chronic and acute wounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103607983A CN103607983A (en) | 2014-02-26 |
| CN103607983B true CN103607983B (en) | 2016-08-17 |
Family
ID=46146915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280029311.XA Active CN103607983B (en) | 2011-04-15 | 2012-04-13 | Hydrocellular absorbent dressing and the purposes in processing chronic wounds and acute wounds thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9452086B2 (en) |
| EP (1) | EP2696827B1 (en) |
| JP (1) | JP5947881B2 (en) |
| KR (1) | KR101925655B1 (en) |
| CN (1) | CN103607983B (en) |
| BR (1) | BR112013026418B1 (en) |
| CA (1) | CA2832883C (en) |
| DK (1) | DK2696827T3 (en) |
| ES (1) | ES2638906T3 (en) |
| FR (1) | FR2974004B1 (en) |
| MX (1) | MX345714B (en) |
| PT (1) | PT2696827T (en) |
| RU (1) | RU2586313C2 (en) |
| SG (1) | SG194487A1 (en) |
| WO (1) | WO2012140377A1 (en) |
| ZA (1) | ZA201307829B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2993182B1 (en) | 2012-07-13 | 2014-10-17 | Urgo Lab | DRESSING WITH PROLONGED RELEASE OF ASSETS |
| FR3015229B1 (en) | 2013-12-19 | 2021-01-22 | Commissariat Energie Atomique | ARTICLE FOR ABSORBING A PHYSIOLOGICAL LIQUID, IN PARTICULAR DRESSING |
| FR3015230B1 (en) | 2013-12-19 | 2020-08-07 | Commissariat Energie Atomique | ARTICLE FOR ABSORBING A PHYSIOLOGICAL LIQUID, IN PARTICULAR DRESSING |
| CN103637876A (en) * | 2013-12-25 | 2014-03-19 | 浙江隆泰医疗科技股份有限公司 | Medical fixing adhesive tape |
| GB201404947D0 (en) * | 2014-03-19 | 2014-04-30 | Medtrade Products Ltd | Wound dressing |
| GB2526267B (en) * | 2014-05-14 | 2020-10-28 | Brightwake Ltd | Dressing for surgical drain |
| WO2016040695A1 (en) | 2014-09-10 | 2016-03-17 | C.R. Bard, Inc. | Protective dressing for skin-placed medical device |
| CN104984382B (en) * | 2015-03-23 | 2017-06-13 | 长春理工大学 | Degradable trauma plaster of medicament slow release and preparation method thereof |
| WO2017018315A1 (en) * | 2015-07-24 | 2017-02-02 | ニチバン株式会社 | Skin-suturing tape or reinforcing tape used after suturing skin |
| FR3053892A1 (en) * | 2016-07-12 | 2018-01-19 | Urgo Recherche Innovation Et Developpement | DRESSING FOR THE CONTROLLED AND PROLONGED RELEASE OF METFORMIN |
| FR3056100B1 (en) * | 2016-09-20 | 2019-07-05 | Urgo Recherche Innovation Et Developpement | ABSORBENT DRESSING COMPRISING A HYDRODELITABLE SUPERABSORBENT NON-WOVEN |
| US20200022845A1 (en) * | 2016-11-24 | 2020-01-23 | Hiroaki Rikihisa | Tape product |
| IL250163A (en) * | 2017-01-17 | 2017-12-31 | Nomberg Sivan | Multiple-use pad |
| FR3068974B1 (en) * | 2017-07-12 | 2019-08-02 | Urgo Recherche Innovation Et Developpement | DRESSING FOR THE CONTROLLED AND PROLONGED DELIVERY OF ASSETS |
| CN112312827A (en) * | 2018-06-15 | 2021-02-02 | 科洛普拉斯特公司 | Wound dressing and method for producing a wound dressing |
| US11007083B2 (en) * | 2018-08-28 | 2021-05-18 | Aatru Medical, LLC | Dressing |
| US11666680B2 (en) | 2018-08-28 | 2023-06-06 | Aatru Medical, LLC | Dressing |
| CN109208335B (en) * | 2018-09-05 | 2021-05-11 | 杭州鸿江纺织印染有限公司 | After-finishing process of fabric |
| AU2019337364A1 (en) * | 2018-09-11 | 2021-05-13 | Beta Medtech Pte. Ltd. | System and device for evaluating parameters pertaining to health of an area of interest on a patient |
| ES2969517T3 (en) * | 2018-12-21 | 2024-05-21 | Hartmann Paul Ag | Super absorbent wound dressing with silicone layer in contact with the wound |
| FR3098105B1 (en) | 2019-07-02 | 2023-05-19 | Safran Coating | Dressing with improved fluid distribution. |
| FR3133122B1 (en) | 2022-03-03 | 2024-03-01 | Urgo Rech Innovation Et Developpement | Modular dressing |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1116516A (en) * | 1994-04-08 | 1996-02-14 | 庄臣消费品有限公司 | Conformable adhesive bandages |
| CN2383500Y (en) * | 1999-08-13 | 2000-06-21 | 中国原子能科学研究院 | Hydrogel composite wound dressing |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE455466C (en) | 1986-03-10 | 1993-07-05 | Moelnlycke Ab | Conveyor Belt for Dangerous Sores |
| GB2192142B (en) | 1986-07-04 | 1990-11-28 | Johnson & Johnson | Wound dressing |
| ATE65528T1 (en) | 1987-07-17 | 1991-08-15 | Smith & Nephew | HYDROPHILIC POLYURETHANE FOAM. |
| FR2618337B1 (en) | 1987-07-22 | 1989-12-15 | Dow Corning Sa | SURGICAL DRESSING AND PROCESS FOR MAKING SAME |
| US4901714A (en) | 1988-09-09 | 1990-02-20 | E. R. Squibb & Sons, Inc. | Bandage |
| JP2786650B2 (en) * | 1989-02-01 | 1998-08-13 | 旭化成工業株式会社 | Adhesive plaster |
| GB8908490D0 (en) | 1989-04-14 | 1989-06-01 | Ici Plc | Prepolymers |
| US5104909A (en) | 1989-09-21 | 1992-04-14 | W. R. Grace & Co.-Conn. | Water-absorbent, high capacity polyurethane foams |
| GB9117913D0 (en) | 1991-08-20 | 1991-10-09 | Smith & Nephew | Polyurethane foams |
| SE500973C2 (en) * | 1992-03-30 | 1994-10-10 | Moelnlycke Ab | Absorbent wound dressing |
| GB9311838D0 (en) | 1993-06-08 | 1993-07-28 | Ici Plc | Process for making flexible foams |
| GB9413932D0 (en) | 1994-07-11 | 1994-08-31 | C V Lab Ltd | Wound dressing manufacture and use |
| RO120139B1 (en) | 1994-11-22 | 2005-09-30 | Imperial Chemical Industries Plc | Process for preparing flexible polyurethane foams |
| US6096942A (en) | 1998-04-24 | 2000-08-01 | Pabban Development Inc. | Surgical dressing, and process for manufacturing same |
| US6548727B1 (en) * | 2000-02-17 | 2003-04-15 | 3M Innovative Properties Company | Foam/film composite medical articles |
| JP4550230B2 (en) * | 2000-06-26 | 2010-09-22 | 日東電工株式会社 | Emergency bandage |
| RU19753U1 (en) * | 2001-04-04 | 2001-10-10 | Филатов Владимир Николаевич | FAST FIXING BANDAGE |
| GB2380135B (en) * | 2001-09-27 | 2005-01-12 | Johnson & Johnson Medical Ltd | Therapeutic wound dressing |
| DK1583493T3 (en) * | 2002-12-31 | 2015-07-27 | Bsn Medical Gmbh | Wound dressing |
| DE10301835A1 (en) * | 2003-01-20 | 2004-07-29 | Beiersdorf Ag | Plaster for dressing wounds has clear fixing film and wound dressing with visible printing on side remote from wound, printed directly on dressing or as normal or mirror image on film bonded to dressing |
| DK1592727T3 (en) | 2003-02-14 | 2012-02-27 | Dow Global Technologies Llc | Hydrophilic polyurethane polymers derived from an MDI-based isocyanate-terminated prepolymer |
| JP4141898B2 (en) * | 2003-05-22 | 2008-08-27 | 玉川衛材株式会社 | Method for producing wound protective agent |
| FR2904214B1 (en) * | 2006-07-28 | 2009-02-27 | Gibaud Soc Par Actions Simplif | DEVICE FOR PROTECTING AND / OR HEALING |
| ATE460913T1 (en) | 2006-10-13 | 2010-04-15 | Coloplast As | WOUND DRESSING |
| ATE494914T1 (en) * | 2006-11-07 | 2011-01-15 | Hartmann Paul Ag | MULTI-LAYER ABSORBENT WOUND DRESSING WITH A HYDROPHILIC WOUND CONTACT LAYER |
| WO2008146529A1 (en) * | 2007-05-30 | 2008-12-04 | Piac Co., Ltd. | Fabric containing x-ray-detectable material, adhesive plaster for x-ray detection, and process for producing adhesive plaster for x-ray detection |
| GB2461019B (en) | 2008-04-25 | 2013-06-05 | Medtrade Products Ltd | Haemostatic material |
| SE533841C2 (en) * | 2009-06-15 | 2011-02-01 | Moelnlycke Health Care Ab | Wound dressing with high fluid handling capacity |
-
2011
- 2011-04-15 FR FR1153325A patent/FR2974004B1/en active Active
-
2012
- 2012-04-13 CN CN201280029311.XA patent/CN103607983B/en active Active
- 2012-04-13 MX MX2013012051A patent/MX345714B/en active IP Right Grant
- 2012-04-13 WO PCT/FR2012/050811 patent/WO2012140377A1/en active Application Filing
- 2012-04-13 KR KR1020137027044A patent/KR101925655B1/en active IP Right Grant
- 2012-04-13 US US14/111,850 patent/US9452086B2/en active Active
- 2012-04-13 BR BR112013026418-7A patent/BR112013026418B1/en not_active IP Right Cessation
- 2012-04-13 EP EP12722416.0A patent/EP2696827B1/en active Active
- 2012-04-13 CA CA2832883A patent/CA2832883C/en active Active
- 2012-04-13 PT PT127224160T patent/PT2696827T/en unknown
- 2012-04-13 JP JP2014504382A patent/JP5947881B2/en active Active
- 2012-04-13 DK DK12722416.0T patent/DK2696827T3/en active
- 2012-04-13 SG SG2013076534A patent/SG194487A1/en unknown
- 2012-04-13 ES ES12722416.0T patent/ES2638906T3/en active Active
- 2012-04-13 RU RU2013150840/14A patent/RU2586313C2/en not_active IP Right Cessation
-
2013
- 2013-10-21 ZA ZA2013/07829A patent/ZA201307829B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1116516A (en) * | 1994-04-08 | 1996-02-14 | 庄臣消费品有限公司 | Conformable adhesive bandages |
| CN2383500Y (en) * | 1999-08-13 | 2000-06-21 | 中国原子能科学研究院 | Hydrogel composite wound dressing |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012241649A1 (en) | 2013-10-31 |
| JP2014514078A (en) | 2014-06-19 |
| KR20140107106A (en) | 2014-09-04 |
| BR112013026418A2 (en) | 2020-08-11 |
| ZA201307829B (en) | 2015-01-28 |
| FR2974004A1 (en) | 2012-10-19 |
| BR112013026418B1 (en) | 2021-05-25 |
| CN103607983A (en) | 2014-02-26 |
| MX345714B (en) | 2017-02-13 |
| KR101925655B1 (en) | 2018-12-05 |
| JP5947881B2 (en) | 2016-07-06 |
| ES2638906T3 (en) | 2017-10-24 |
| SG194487A1 (en) | 2013-12-30 |
| AU2012241649B2 (en) | 2016-03-10 |
| DK2696827T3 (en) | 2017-09-11 |
| EP2696827B1 (en) | 2017-05-31 |
| FR2974004B1 (en) | 2014-05-02 |
| RU2586313C2 (en) | 2016-06-10 |
| CA2832883A1 (en) | 2012-10-18 |
| CA2832883C (en) | 2019-07-02 |
| EP2696827A1 (en) | 2014-02-19 |
| US20140142526A1 (en) | 2014-05-22 |
| US9452086B2 (en) | 2016-09-27 |
| RU2013150840A (en) | 2015-05-20 |
| MX2013012051A (en) | 2014-07-28 |
| WO2012140377A1 (en) | 2012-10-18 |
| PT2696827T (en) | 2017-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103607983B (en) | Hydrocellular absorbent dressing and the purposes in processing chronic wounds and acute wounds thereof | |
| CN103596529B (en) | Strong absorbent, thin adhesiveness dressing | |
| DK2688533T3 (en) | PRIMARY COMPRESSION FOR MOISTURIZED WOOL HEALTH AND PROCEDURE FOR PREPARING PRIMARY COMPRESSION | |
| JP2007296361A (en) | Adhesive bandage | |
| JP6953568B2 (en) | Wound bandage assembly | |
| JP6679567B2 (en) | Two-stage wound dressing assembly | |
| US20160374862A1 (en) | Composite material for filling cavity wounds | |
| JP2008136852A (en) | Adhesive gauze bandage, and method for manufacturing the same | |
| JP2008136852A5 (en) | ||
| AU2012241649B9 (en) | Hydrocellular absorbent dressing, and uses thereof for the treatment of chronic and acute wounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1194959 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170830 Address after: Singapore Singapore Patentee after: HCP Healthcare Asia Pte. Ltd. Address before: Paris France Patentee before: VIVA Technology Ltd. Effective date of registration: 20170830 Address after: Paris France Patentee after: VIVA Technology Ltd. Address before: French Shenif Patentee before: Industrial Research and Development Simplified JSC Effective date of registration: 20170830 Address after: French Shenif Patentee after: Industrial Research and Development Simplified JSC Address before: French Shenif Co-patentee before: Industrial Research and Development Simplified JSC Patentee before: Yu Ergeshiyanshi |
|
| TR01 | Transfer of patent right | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1194959 Country of ref document: HK |